Researchers reveal how SARS-CoV-2 virus protein damages heart tissue

The virus that causes COVID-19, SARS-CoV-2, has a particular protein that harms heart cells, according to research. Researchers found the drug to counteract the protein's damaging effects on the heart.

Their findings, based on research by the University of Maryland School of Medicine's (UMSOM) Center for Precision Disease Modeling with fruit flies and mouse heart cells, were published on Sept. 30, 2022, in Communications Biology, a Nature journal.

People infected with COVID-19 are at a significantly higher risk for developing inflammation of the heart muscle, abnormal heart rhythms, blood clots, stroke, heart attacks, and heart failure for at least a year after infection, compared to those who have not been infected with the virus. Although scientists rapidly developed vaccines and medications to lessen the severity of COVID-19 disease, these therapies do not protect the heart or other organs from the damage that can be done by even a mild infection.

"To treat patients in the long run, we must first understand the mechanism behind what is causing the disease. Our research shows that individual SARS-CoV-2 proteins can each do major damage to specific tissues in the body -- similar to what has been found for other viruses like HIV and Zika," said senior author Zhe Han, PhD, Professor of Medicine and Director of the Center for Precision Disease Modeling at UMSOM. "By identifying these processes of injury in each tissue, we can test drugs to see whether any can reverse this damage; those drugs that show promise can then be further tested in clinical research studies."

Last year, Dr. Han and his research team identified the most toxic SARS-CoV-2 proteins in studies using fruit flies and human cells. They found a promising drug selinexor reduced the toxicity of one of these proteins, but not the other one, known as Nsp6.

In their latest study, they found that Nsp6 turned out to be the most toxic SARS-CoV-2 protein in the fly heart. Next, they found that the Nsp6 protein hijacked the fruit fly's cells in its heart to turn on the glycolysis process, which enables cells to burn the sugar glucose for energy. Typically, heart cells use fatty acids as an energy source, but switch over to sugar metabolism during heart failure as these cells to try to repair the damaged tissue. The researchers also found the Nsp6 protein did added damage by disrupting the cell's powerhouse, called the mitochondria, which produces energy from sugar metabolism.

The team then blocked sugar metabolism in fruit flies and mouse heart cells using the drug 2-deoxy-D-glucose (2DG). They found that the drug reduced the heart and mitochondria damage caused by the Nsp6 viral protein.

"We know that some viruses hijack the infected animal's cell machinery to change its metabolism to steal the cell's energy source, so we suspect SARS-CoV-2 does something similar. The viruses can also use the byproducts of sugar metabolism as building blocks to make more viruses," said Dr. Han. "So, we predict this drug that changes the metabolism in the heart back to what it was before infection would be bad for the virus, by both cutting off its energy supply and eliminating the pieces it needs to replicate."

The researchers said that fortunately 2DG is inexpensive and is used regularly in laboratory research. Although 2DG has not been approved by the U.S. Food and Drug Administration to treat disease, the drug is currently in clinical trials for treatment of COVID-19 in India.

"Too many Americans who have recovered from COVID wind up with dangerous heart conditions weeks or months later, and we need to learn the fundamental reasons for why this is happening," said Mark T. Gladwin, MD, Vice President for Medical Affairs at University of Maryland, Baltimore and the John Z. and Akiko K. Bowers Distinguished Professor and Dean, UMSOM. "With this research elucidating the pathways of the Nsp6 protein, we can refine the treatments we target for future research with the ultimate aim of reversing further heart damage in these patients."

( With inputs from ANI )